The Latest Cardiac and Vascular News
ACC.22: Late-breaking data show CoreValveTM and EvolutTM is the only platform to out-perform surgery in valve durability at five years Medtronic today unveiled new insights from a pooled analysis of high and intermediate risk patients from the CoreValve/Evolut program, showing a lower occurrence in structural valve deterioration (SVD) in patients […]
DUBLIN and SAN DIEGO – September 24, 2018 – Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced new data presented at the 30th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation. Over the weekend, investigators presented the longest-term data to-date from […]
DUBLIN – July 31, 2017 – Medtronic plc (NYSE:MDT) today announced CE (Conformité Européenne) mark and European launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at intermediate, high or extreme risk for open heart surgery. Clinical data for the Evolut PRO valve […]
DUBLIN – July 10, 2017 – Medtronic plc (NYSE: MDT) today announced the expanded U.S. Food and Drug Administration (FDA) approval of the self-expanding CoreValve(TM) Evolut(TM) transcatheter aortic valve replacement (TAVR) platform to include patients with symptomatic severe aortic stenosis who are at an intermediate risk for open-heart surgery. With hemodynamic […]
Press Release Medtronic Receives FDA Approval for CoreValve(TM) Evolut(TM) Pro Transcatheter Valve with Advanced Sealing DUBLIN – March 22, 2017 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval and U.S. launch of the CoreValve(TM)Evolut(TM) PRO valve for the treatment of severe aortic stenosis for symptomatic […]
